Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 15/20 | 0.40 |
| ▸ | TDO2 | P48775 | 14/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20743952 | 0.84 | MAPK1 (0.41) | IDO1TDO2KDM4EALDH1A1HPGD | |
| SCHEMBL20743924 | 0.81 | IDO1 (0.47) | IDO1TDO2 | |
| SCHEMBL22188394 | 0.80 | IDO1 (0.37) | IDO1TDO2MEN1KMT2A | |
| SCHEMBL22188384 | 0.79 | IDO1 (0.50) | IDO1TDO2KDM4EALDH1A1HPGD | |
| SCHEMBL22188381 | 0.72 | IDO1 (0.51) | IDO1TDO2 | |
| SCHEMBL33526512 | 0.71 | DAPK3 (0.35) | KDM4EALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL19915857 | 0.70 | IDO1 (0.39) | IDO1KDM4EALDH1A1HPGDTSHR | |
| SCHEMBL20743971 | 0.70 | MAPK1 (0.41) | IDO1TDO2KDM4EALDH1A1HPGD | |
| SCHEMBL7497739 | 0.69 | MAPK1 (0.43) | IDO1TDO2KDM4EALDH1A1HPGD | |
| SCHEMBL28397264 | 0.68 | IDO1 (0.50) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-03-08 | — | — | US | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| EP-3740493-B1 | INHIBTEURS DE L'INDOLEAMINE 2,3-DIOXYGÉNASE ET/OU DU TRYPTOPHANE DIOXYGÉNASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-12-01 | — | — | EP | disclosed |
| EP-3668880-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-10-06 | — | — | EP | disclosed |
| EP-3668880-B1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-10-06 | — | — | EP | disclosed |
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3740493-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-11-25 | — | — | EP | disclosed |
| CN-111601810-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-08-28 | — | — | CN | disclosed |
| US-20200216467-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2020-07-09 | — | — | US | disclosed |
| EP-3668880-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | Idorsia Pharmaceuticals Ltd (CH) | 2020-06-24 | — | — | EP | disclosed |
| CN-110997682-A | Inhibitors of indoleamine 2, 3-dioxygenase and/or tryptophan 2, 3-dioxygenase | 爱杜西亚药品有限公司 | 2020-04-10 | — | — | CN | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034725-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405696-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, TDO2, IDO1 | IDO1 3/4885TDO2 2/4885KDM4E 1391/4885 |
| US-20200216467-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE AND/OR TRYPTOPHAN 2,3-DIOXYGENASE | IDO2, IDO1, TDO2 | IDO1 2/4885TDO2 3/4885KDM4E 1390/4885 |
| US-11267824-B2 | Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase | IDO2, IDO1, TDO2 | IDO1 2/4885TDO2 3/4885KDM4E 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.